Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Early detection of cancers on the horizon with supersensitive nanodevice

Early detection of cancers on the horizon with supersensitive nanodevice

Extremely early detection of cancers and other diseases is on the horizon with a supersensitive nanodevice being developed at The University of Alabama in Huntsville in collaboration with The Joint School of Nanoscience and Nanoengineering in Greensboro, NC. [More]
Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. [More]
ZERO donates mobile health vehicles to Buddhist Tzu Chi Medical Foundation, LSU Health Sciences Center

ZERO donates mobile health vehicles to Buddhist Tzu Chi Medical Foundation, LSU Health Sciences Center

ZERO - The End of Prostate Cancer recently announced the donation of two mobile health vehicles to LSU Health Sciences Center and Buddhist Tzu Chi Medical Foundation. Through a competitive process, the vehicles have been awarded to two reputable health service providers. [More]
Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Analysis of circulating tumor cells (CTCs) in a mouse model of pancreatic cancer identified distinct patterns of gene expression in several groups of CTCs, including significant differences from the primary tumor that may contribute to the ability to generate metastases. [More]
Researchers test novel robotic system to improve prostate cancer biopsies

Researchers test novel robotic system to improve prostate cancer biopsies

A novel robotic system that can operate inside the bore of an MRI scanner is currently being tested as part of a biomedical research partnership program at Brigham and Women's Hospital in Boston with the aim of determining if the robot, in conjunction with real-time MRI images, can make prostate cancer biopsies faster, more accurate, less costly, and less discomforting for the patient. [More]
Guidelines recommending routine prostate cancer screening for elderly men have minimal effect

Guidelines recommending routine prostate cancer screening for elderly men have minimal effect

The effect of guidelines recommending that elderly men should not be routinely screened for prostate cancer "has been minimal at best," according to a new study led by researchers at Henry Ford Hospital. [More]
New approach to imaging metastatic tumors

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. [More]
Scientists find 23 new genetic variants that increase risk for prostate cancer

Scientists find 23 new genetic variants that increase risk for prostate cancer

In an analysis of genetic information among more than 87,000 men, a global team of scientists says it has found 23 new genetic variants - common differences in the genetic code -- that increase a man's risk for prostate cancer. The so-called "meta-analysis," believed to be the largest of its kind, has revealed once hidden mutations among men in a broad array of ethnic groups comprising men of European, African, Japanese and Latino ancestry. [More]
Novel genetic discovery identifies new avenues for prostate cancer treatment

Novel genetic discovery identifies new avenues for prostate cancer treatment

A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment. [More]
Global study identifies another 23 new prostate cancer risk loci

Global study identifies another 23 new prostate cancer risk loci

Scientists could soon better predict a man's risk of getting prostate cancer after a worldwide team of researchers carried out the largest-ever analysis of the cancer's genetic biomarkers, reported in Nature Genetics today. [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]
Assessing genetic variants can help identify men with increased risk of prostate cancer

Assessing genetic variants can help identify men with increased risk of prostate cancer

Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease. [More]
BGI-VPC Joint Research Laboratory to apply genome research to develop new cancer therapies

BGI-VPC Joint Research Laboratory to apply genome research to develop new cancer therapies

BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre, a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
American men have worse access to reproductive and sexual health care, shows research

American men have worse access to reproductive and sexual health care, shows research

Compared with women, American men have worse access to reproductive and sexual health care, research shows, a disparity fueled in part by the lack of standard clinical guidelines on the types and timing of exams, tests and treatments that should be offered to all men of reproductive age. [More]
Experts share tips on prevention of prostate cancer

Experts share tips on prevention of prostate cancer

Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually. [More]
Low free testosterone predicts prostate cancer reclassification

Low free testosterone predicts prostate cancer reclassification

Lower levels of free testosterone predict an increased likelihood of disease reclassification in men with prostate cancer, researchers report. [More]
Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International plc announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII. [More]
Radioactive tracer with PET MRI imaging helps prostate cancer patients avoid unnecessary surgery

Radioactive tracer with PET MRI imaging helps prostate cancer patients avoid unnecessary surgery

Researchers at the Norwegian University of Science and Technology are pioneering the use of a radioactive tracer in combination with PET MRI imaging to help some prostate cancer patients avoid lengthy and unnecessary surgery. [More]